Patents Examined by Jennifer Kim
  • Patent number: 7897646
    Abstract: The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: March 1, 2011
    Assignee: AstraZeneca AB
    Inventors: Carl-Axel Bauer, Jan Trofast
  • Patent number: 7468390
    Abstract: The invention relates a pharmaceutical composition comprising a combination of: (i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof; and (ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, heart failure, such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, sclero
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: December 23, 2008
    Assignee: Novartis AG
    Inventors: Gary Michael Ksander, Randy Lee Webb
  • Patent number: 7439248
    Abstract: The present invention provides a new stable pharmaceutical composition containing 5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiadiazolidine-2,4-dione as active ingredient.
    Type: Grant
    Filed: November 30, 1999
    Date of Patent: October 21, 2008
    Assignees: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.
    Inventors: Helle Weibel, Thyge Borup Hjorth
  • Patent number: 7439268
    Abstract: The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one or a combination of one or a combination of the following: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate. In another embodiment the prodrug is converted into the florfenicol in vivo by the action of one or more endogenous esterases. The invention also provides new compounds, pharmaceutical compositions containing the compounds, and methods for their administration.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: October 21, 2008
    Assignee: Idexx Laboratories
    Inventors: Yerramilli V. S. N. Murthy, Robert H. Suva
  • Patent number: 7429576
    Abstract: Novel methods for the medical treatment and/or inhibition of the development of osteoporosis, breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warm-blooded animals including humans involving administration of selective estrogen receptor modulator particularly compounds having the general structure: and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3?, 17?-diol and compounds converted in vivo to one of the foregoing presursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursor is disclosed for the medical treatment and/or inhibition of the development of osteoporosis. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.
    Type: Grant
    Filed: December 30, 2003
    Date of Patent: September 30, 2008
    Assignee: Endorecherche, Inc.
    Inventor: Fernand Labrie
  • Patent number: 7429599
    Abstract: This invention generally relates to methods for treating or preventing a condition responsive to JNK inhibition, such as a metabolic condition, comprising administering to a patient in need thereof an effective amount of an Anilinopyrimidine Derivative having the following structure: or a pharmaceutically acceptable salt thereof, wherein R1 through R6 are as defined herein.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: September 30, 2008
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Yoshitaka Satoh, Shripad S. Bhagwat
  • Patent number: 7423066
    Abstract: Methods, pharmaceutical compositions, and compounds for reducing body weight, modulating body lipid metabolism, and reducing food intake in mammals are provided. The compounds of the invention include fatty acid ethanolamide compounds, homologues and analogs of which the prototype is the endogenous fatty acid ethanolamide, oleoylethanolamide.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: September 9, 2008
    Assignee: The Regents of the University of California
    Inventors: Daniele Piomelli, Fernando Rodriguez de Fonseca
  • Patent number: 7422998
    Abstract: Suitable for controlling harmful plants in sugar beet crops composed of tolerant or resistant mutants or transgenic sugar beet plants are herbicide combinations (A)+(B), if appropriate in the presence of safeners, with an effective content of (A) broad-spectrum herbicides from the group (A1) glufosinate (salts) and related compounds, (A2) glyphosate (salts) and related compounds such as sulfosate and (A3) imidazolinones or their salts and (B) herbicides from the group consisting of (B0) one or more structurally different herbicides from the abovementioned group (A) or (B1) foliar- and predominantly soil-acting herbicides which are active against monocotyledonous and dicotyledonous harmful plants, or (B2) herbicides which are active predominantly against dicotyledonous harmful plants, and (B3) herbicides which are predominantly foliar-acting and which can be employed against monocotyledonous harmful plants, or (B4) herbicides which are both foliar- and soil-acting and which can be employed against monocot
    Type: Grant
    Filed: June 22, 2004
    Date of Patent: September 9, 2008
    Assignee: Aventis CropScience GmbH
    Inventors: Erwin Hacker, Hermann Stuebler, Hermann Bieringer, Lothar Willms
  • Patent number: 7419998
    Abstract: Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (I), in which Z is H, R1 is H, or RACO where RA is C1-10alkyl or an amino acid, R2 is H, OH, or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R3 is H, CORA where RA is as previously defined, CO2RC where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H.
    Type: Grant
    Filed: December 28, 2004
    Date of Patent: September 2, 2008
    Assignee: Novogen Research Pty Ltd
    Inventors: Graham Edmund Kelly, George Eustace Joannou
  • Patent number: 7402591
    Abstract: An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1. The analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: July 22, 2008
    Assignee: Reckitt Benckiser Healthcare (UK) Limited
    Inventors: Christopher Bourne Chapleo, Nicolas Calvert Varey, Keith McCormack
  • Patent number: 7399784
    Abstract: Anti-obesity compositions include medicaments comprising predetermined amounts of a phytyl substituted chromanol and an obesity-promoting drug, wherein: said medicament is in unit dosage form suitable for pharmaceutical administration; said phytyl substituted chromanol is a gamma-tocopherol, delta-tocopherol, alpha-tocotrienol, gamma-tocotrienol or delta-tocotrienol; said obesity-promoting drug is a corticosteroid or an anti-diabetes drug such as a hypoglycemic drug, starch blocker, glucose production blocker or insulin sensitizer.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: July 15, 2008
    Assignee: Children's Hospital & Research Center at Oakland
    Inventors: Bruce N. Ames, Qing Jiang
  • Patent number: 7396854
    Abstract: The present invention relates to a method of treatment of hot flushes with a 5-HT2C receptor agonist and in particular to the use of the selective 5-HT2C receptor agonists 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-piperazine and (S)-(+)-3-[(2,3-dihydro-5-methoxy-1H-inden-4-yl)oxy-pyrrolidine or pharmaceutically acceptable acid addition salts thereof for the manufacture of a pharmaceutical formulation adapted for the treatment of hot flushes.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: July 8, 2008
    Assignee: N.V. Organon
    Inventor: Hermanus Henricus Gerardus Berendsen
  • Patent number: 7396860
    Abstract: The subject invention provides a method for treating amyotrophic lateral sclerosis (ALS) in a subject in need of such treatment comprising administering to the subject R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof alone or in combination with 2-amino-6-trifluoromethoxy benzothiazole in amounts effective to treat ALS in the subject.
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: July 8, 2008
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Eran Blaugrund, Ruth Levy
  • Patent number: 7393864
    Abstract: The present invention provides methods for the modulation of vascular tone in a patient having compromised vascular tissue, which methods comprise the administration of a chloride channel blocking agent or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 15, 2001
    Date of Patent: July 1, 2008
    Assignee: University of Iowa Research Foundation
    Inventors: Fred S. Lamb, Brian C. Schutte, Baoli Yang
  • Patent number: 7384646
    Abstract: The purpose of the present invention is to provide antiseptic disinfectant, and cosmetics and toiletries, medicine or food containing the same, which enhance the antibacterial activity that 1,2-alkanediol originally have against a broad range of strains by compounding 1,2-alkanediol with 5-10 carbons and a certain fragrance component. The present invention relates to an antiseptic disinfectant, and cosmetics and toiletries, medicine or food containing the same, which include 1,2-alkanediol with 5-10 carbons, and one or more materials selected from a group of citral, geraniol, nerol, perillaldehyde, ?-terpineol, dodecanol and L-carvone.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: June 10, 2008
    Assignee: Mandom Corporation
    Inventors: Aki Kobayashi, Hiroya Okamoto, Fumihiro Okada
  • Patent number: 7371756
    Abstract: 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the treatment of sub-type anxiety disorders chosen from the sub-types: panic disorder with or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized anxiety disorder, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia, and fibromyalgia. A preferred salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: May 13, 2008
    Assignee: Merck Patent GmbH
    Inventors: Gerd Bartoszyk, Christoph Seyfried, Christoph Von Amsterdam, Henning Boettcher, Ewen Sedman
  • Patent number: 7361681
    Abstract: The present invention relates to the treatment of amyotrophic lateral sclerosis (ALS) and/or the improvement of motor function in individuals in need of such improvement using a melatonin compound or a pharmaceutical salt of the melatonin compound.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: April 22, 2008
    Assignee: SYGNIS Bioscience GmbH & Co. KG
    Inventors: Hannelore Ehrenreich, Ruediger Hardeland, Klaus-Armin Nave, Jochen Weishaupt
  • Patent number: 7361646
    Abstract: This invention relates to the discovery that agents capable of inhibiting the biological action of the glucocorticoid receptor can be used in methods for treating gastroesophageal reflux disease in a subject.
    Type: Grant
    Filed: November 5, 2003
    Date of Patent: April 22, 2008
    Assignee: Corcept Therapeutics, Inc.
    Inventor: Joseph K. Belanoff
  • Patent number: 7348321
    Abstract: The invention relates to the use of flumazenil in developing a drug used for the sequential administration of small quantities of flumazenil at short intervals, until a therapeutically effective quantity is administered to treat alcohol dependence.
    Type: Grant
    Filed: July 15, 2003
    Date of Patent: March 25, 2008
    Assignee: Hythiam, Inc.
    Inventor: Juan Jose Legarda IbaƱez
  • Patent number: 7345096
    Abstract: The present invention relates to the use of compounds and composition of compounds that modulate norepinephrine levels for the prevention and treatment of vasomotor symptoms, such as hot flush, caused by, inter alia, thermoregulatory dysfunctions.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: March 18, 2008
    Assignee: Wyeth
    Inventors: Darlene Coleman Deecher, Istvan Jozsef Merchenthaler, Liza Leventhal, Kimberly Jean Sipe, Lawrence Thomas O'Connor